Zenas Biopharma (usa), Llc
Clinical trials sponsored by Zenas Biopharma (usa), Llc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a B-Cell blocker tame lupus? Results expected Sep 2026 (estimated)
-
Can a B-Cell blocker tame lupus?
Disease control OngoingThis phase 2 trial is testing whether an experimental drug called obexelimab can safely reduce disease activity in people with systemic lupus erythematosus (SLE). The study enrolls about 190 adults aged 18 to 70 with active lupus. Participants are randomly assigned to receive eit…
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug aims to stop Flare-Ups in rare autoimmune disease
Disease control OngoingThis study tests a drug called obexelimab to see if it can prevent flare-ups in people with IgG4-related disease, a rare condition where the immune system attacks the body's own tissues. About 194 adults with active disease will receive either the drug or a placebo. The main goal…
Phase 3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New MS drug shows promise in reducing brain lesions
Disease control OngoingThis study tests whether obexelimab can safely reduce brain lesions in people with relapsing multiple sclerosis (MS). About 93 adults with active relapses or recent MRI lesions will receive either the drug or a placebo. The main goal is to count new brain lesions on MRI scans ove…
Phase 2 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC